November 26, 2022

VSS Scientific Updates During Pandemic Times #46

1. California Hospitals Treating Patients in Tents as the Number of Positive Flu Tests is Up 259 Percent from Last Year

“The move comes amid a rise in flu symptoms in emergency room patients in San Diego County. The dominant strain, H3N2, appears to lead to more severe illnesses than usual.”

2. China's COVID Cases Rise, Record Daily Numbers Seen in Beijing and Other Cities

“The record highs also come as official media reported that work to remove "pop-up windows" on smartphone health apps that prevent people from entering or returning to Beijing is "in progress" and in effect in many places. The health app requires a negative PCR test to allow unrestricted mobility.”

3. COVID Pandemic Led to Surge in Superbug Infections, EU Agency Says

From Geert: “The surge in such infections (in highly C-19 vaccinated countries) is not due to a kind of evolution of these common pathogens into a ‘superbug’ phenotype that could allegedly have been driven by longer stays in the hospital and more antibiotic prescriptions!

It is merely due to the fact that all attention of antigen-presenting cells (APCs) in highly vaccinated populations is now focused on stimulating tons of MHC-unrestricted cytolytic T cells (CTLs) to eliminate SARS-CoV-2-infected host cells. While being hijacked for this purpose, APCs cannot sufficiently take care of their other ‘professional’ duties, which is to serve as a general platform for antigen presentation to the host immune system.”

4. Evasive Spike Variants Elucidate the Preservation of T Cell Immune Response to the SARS-CoV-2 Omicron Variant

From Geert: “I have written at least 5-6 articles to debunk the role of T cells in controlling the pandemic.

People obviously do not understand the difference between T cell-mediated antigenicity and T cell-mediate sterilizing immunity. Of course: great conservation of T cells epitopes across a multitude of variants and even other CoVs. However, no evidence whatsoever that there is widespread induction of cytolytic memory T cells capable of killing SC-2-infected host cells.

In the absence of those, there is no role for ‘their’ T cells to play in curtailing viral transmission and stopping this pandemic. Consequently, there is no broadly cross-protective MHC cl I-unrestricted epitope that could be used in a vaccine to induce cytolytic memory T cells and broadly protect people from productive infection and C-19 disease, regardless of the variant. 

What a waste of time and resources!”

5. The End of Vaccines at ‘Warp Speed’

“Financial and bureaucratic barriers in the United States mean that the next generation of Covid vaccines may well be designed here, but used elsewhere.”

Support our work
Subscribe to our Substack Newsletter

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.

Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.

Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.


Recent Posts
February 28, 2024

Public Hearing Senate Brazil

February 28, 2024

Do the COVID-19 Vaccines Protect Against Severe Disease and Death?

February 18, 2024

VSS Scientific Updates During Pandemic Times #61

Voices for Science and solidarity, © 2023